Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)
NCT01382160
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
69
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL:
adalimumab
Sponsor
University Hospital, Tours